HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S.

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and ...

Psoriatic and rheumatoid arthritis cause similar symptoms, but key differences can help you and your healthcare provider tell them apart.

Mease described guselkumab (Tremfya, Janssen) as a fully human monoclonal antibody that selectively targets the interleukin (IL)-23p19 subunit, which may inhibit IL-23 signaling.

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis ...